Sequential Letrozole and Methotrexate Therapy Role in Treatment of Tubal Ectopic Pregnancy
- Registration Number
- NCT06426979
- Lead Sponsor
- Zagazig University
- Brief Summary
Ectopic pregnancy (EP) is a common condition involving the implantation of fertilized ovum outside the uterine cavity, accounting for 1-2% of all pregnancies. Tubal EP (TEP) is the most common and poses a significant risk to maternal life. Early diagnosis and medical treatment, such as methotrexate (MTX) and the Fallopian tube (FT), have been studied. However, the efficacy of single-dose methotrexate (SD-MTX) is questionable, and the efficacy of two-dose versus SD-MTX for medical management of EP is being evaluated. High estrogens/progesterone ratios can disrupt embryonic motility and lead to TEP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
- Presence of gestational masses of <3.5 cm in its greatest diameter in an intact uterine tube and showed no fetal cardiac activity;
- Absence of hemodynamic manifestations or evidence of intra-peritoneal bleeding on TVU and pre-treatment serum hCG of <3500 IU/L.
- Free of Inclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group LTZ-MTX Methotrexate Letrozole and Methotrexate Therapy's Group Group LTZ-MTX Letrozole Letrozole and Methotrexate Therapy's Group Group MTX Methotrexate Methotrexate Therapy's Group
- Primary Outcome Measures
Name Time Method The Rate of resolution of Tubal Ectopic Pregnancy (TEP) 9 months Role of Letrozole in resolution of Tubal Ectopic Pregnancy (TEP) that was confirmed by TVU and without shifting to surgery.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zagazig university
🇪🇬Zagazig, Ash Sharqia Governorate, Egypt